Advertisement

InFo Hämatologie + Onkologie

, Volume 22, Issue 6, pp 18–22 | Cite as

Schwerpunkt Urothelkarzinom

Perioperative Systemtherapie des muskelinvasiven Harnblasenkarzinoms

  • Christoph OingEmail author
  • Gunhild von Amsberg
  • Carsten Bokemeyer
  • Stefanie Fischer
Schwerpunkt
  • 3 Downloads

Die radikale Zystektomie ist Goldstandard in der Behandlung des muskelinvasiven Harnblasen-karzinoms, jedoch erleiden 50 % der Patienten ein Rezidiv. Eine neoadjuvante Cisplatin-basierte Chemotherapie verbessert das Überleben signifikant, bleibt jedoch weiterhin vielen Patienten vorenthalten. Die Evidenz für die häufiger eingesetzte adjuvante Chemotherapie ist schwächer, aber auch hier scheint ein Überlebensvorteil gegeben. Für Cisplatin-ungeeignete Patienten gab es bislang keine Empfehlung zur perioperativen Systemtherapie. Neue Substanzen, inbesondere Checkpointinhibitoren, eröffnen zukünftig auch in dieser Situation perioperative Therapie-optionen.

Literatur

  1. 1.
    Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms. Leitlinienprogramm Onkologie. 2016; AWMF-Regisitrierungsnummer 032/038OL(Langversion 1.1):1371Google Scholar
  2. 2.
    Madersbacher S et al. Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2003;21(4):690–6CrossRefGoogle Scholar
  3. 3.
    Stein JP et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2001;19(3):666–75CrossRefGoogle Scholar
  4. 4.
    Galsky MD et al. Treatment of patients with metastatic urothelial cancer „unfit“ for Cisplatin-based chemotherapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011;29(17):2432–8CrossRefGoogle Scholar
  5. 5.
    Galsky MD et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. The Lancet Oncology. 2011;12(3):211–4CrossRefGoogle Scholar
  6. 6.
    Grossman HB et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. The New England journal of medicine. 2003;349(9):859–66CrossRefGoogle Scholar
  7. 7.
    Advanced Bladder Cancer Overview C. Neoadjuvant chemotherapy for invasive bladder cancer. The Cochrane database of systematic reviews. 2005(2):CD005246Google Scholar
  8. 8.
    Fairey AS et al. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. Urologic oncology. 2013;31(8):1737–43CrossRefGoogle Scholar
  9. 9.
    Zargar H et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. European urology. 2015;67(2):241–9CrossRefGoogle Scholar
  10. 10.
    Galsky MD et al. Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2016;34(22):2627–35CrossRefGoogle Scholar
  11. 11.
    Peyton CC et al. Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for MuscleInvasive Bladder Cancer. JAMA oncology. 2018;4(11):1535–42CrossRefGoogle Scholar
  12. 12.
    David KA et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. The Journal of urology. 2007;178(2):451–4CrossRefGoogle Scholar
  13. 13.
    Booth CM et al. Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study. Cancer. 2014;120(11):1630–8CrossRefGoogle Scholar
  14. 14.
    Burger M et al. Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: results of a feasibility questionnaire. European urology. 2012;61(5):1070–1CrossRefGoogle Scholar
  15. 15.
    Reardon ZD, Patel SG, Zaid HB, Stimson CJ, Resnick MJ, Keegan KA, et al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. European urology. 2015;67(1):165–70CrossRefGoogle Scholar
  16. 16.
    Leow JJ et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. European urology. 2014;66(1):42–54CrossRefGoogle Scholar
  17. 17.
    Sternberg CN et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, openlabel, randomised phase 3 trial. The Lancet Oncology. 2015;16(1):76–86CrossRefGoogle Scholar
  18. 18.
    Haque W et al. The role of adjuvant chemotherapy in locally advanced bladder cancer. Acta oncologica. 2018;57(4):509–15CrossRefGoogle Scholar
  19. 19.
    Sternberg CN, Donat SM, Bellmunt J, Millikan RE, Stadler W, De Mulder P, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology. 2007;69(1 Suppl):62–79CrossRefGoogle Scholar
  20. 20.
    Galsky MD et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015;121(15):2586–93CrossRefGoogle Scholar
  21. 21.
    Booth CM et al. Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice. Annals of oncology: official journal of the European Society for Medical Oncology. 2014;25(9):1783–8CrossRefGoogle Scholar
  22. 22.
    Donat SM et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. European urology. 2009;55(1):177–85CrossRefGoogle Scholar
  23. 23.
    Leveridge MJ et al. Radical cystectomy and adjuvant chemotherapy for bladder cancer in the elderly: a population-based study. Urology. 2015;85(4):791–8CrossRefGoogle Scholar
  24. 24.
    Pouessel D et al. Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort. Clinical genitourinary cancer. 2017;15(1):e45–e52CrossRefGoogle Scholar
  25. 25.
    Birtle AJ et al. Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2018;36(suppl):abstr 407CrossRefGoogle Scholar
  26. 26.
    Necchi A et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2018:JCO1801148Google Scholar
  27. 27.
    Castellano D et al. A phase II study investigating the safety and efficacy of neoadjuvent atezolizumab in muscle invasive bladder cancer (ABACUS). Ann Oncol. 2018;29(suppl_8):viii303–viii31CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  • Christoph Oing
    • 1
    • 2
    Email author
  • Gunhild von Amsberg
    • 1
  • Carsten Bokemeyer
    • 1
  • Stefanie Fischer
    • 2
    • 3
  1. 1.Klinik für Onkologie, Hämatologie und Knochenmarktransplantation mit Abteilung für PneumologieUniversitätsklinikum Hamburg-EppendorfHamburgDeutschland
  2. 2.Manchester Cancer Research CentreThe University of ManchesterManchesterGroßbritannien
  3. 3.Klinik für Medizinische Onkologie und HämatologieKantonsspital St. GallenSt. GallenSchweiz

Personalised recommendations